News | March 31, 2026
Kenvue unleashes science-driven skincare offensive at American Academy of Dermatology meet
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
The decision is based on the phase 3 DESTINY-Breast11 trial
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
The presentations underscore the company’s deep expertise in dermatology and immunology
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Subscribe To Our Newsletter & Stay Updated
